ALSO NOTED: Russian docs charged over clinical trials; FDA approves new dosing schedule for Twinrix;and much more...

> Three Russian doctors involved in clinical trials for GlaxoSmithKline have been charged with illegal practices, including failure to safeguard the health of infants. Report

> The FDA has approved a faster dosing schedule for GlaxoSmithKline's hepatitis vaccine Twinrix. Report

> Genelabs Technologies has reached agreement with the FDA on an SPA for a Phase III clinical trial of Prestara (prasterone) for lupus. Release

> Pharmexa and Affitech have inked a licensing deal on diabody technology. Release

> Scientists report Alzheimer's vaccine success. Report

> A group of researchers has identified genes that can help a person quit smoking. Report

> Using bacterial enzymes, an international team of researchers have developed a simple method to convert type A, B or AB to group O blood that can be used universally. Report

And Finally... A $750,000 grant will allow a University of Kentucky researcher to take a therapy for macular degeneration into the clinic. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.